Volume 15
Issue 2 October

Article 2

Risks and Benefits of Coronary Computed Tomography Angiography: A
Review
Patrick WI Pau

Follow this and additional works at: https://www.jhkcc.com.hk/journal

Recommended Citation
Patrick WI Pau, Risks and Benefits of Coronary Computed Tomography Angiography: A Review Journal of the Hong
Kong College of Cardiology 2007;15(2) https://doi.org/10.55503/2790-6744.1099
This Review Article is brought to you for free and open access by Journal of the Hong Kong College of Cardiology. It has been
accepted for inclusion in Journal of the Hong Kong College of Cardiology by an authorized editor of Journal of the Hong Kong
College of Cardiology.

Risks and Benefits of Coronary Computed Tomography Angiography:
A Review
PATRICK WI PAU

PAU.: Risks and Benefits of Coronary Computed Tomography Angiography: A Review. Multislice computed
tomography coronary angiography (CTA) is a noninvasive radiology technique that provides high-resolution images
of the coronary artery. It has high sensitivity and specificity for coronary stenosis and can be used to rule out
significant coronary artery disease (CAD), thereby avoiding the risk of invasive coronary angiography. There is a
danger that CTA may be overused as a screening test for CAD in healthy subjects, thereby exposing the patients to
the dangers of adverse reactions to iodinated contrast agents and cancer induction from radiation exposure. Consensus
document has been published for clinical guidance on when it is appropriate to order a CTA. Comparative studies
with stress nuclear myocardial perfusion imaging (MPI) have shown that significant coronary atherosclerosis
demonstrated on CTA may not be associated with ischemia in the same region on MPI. Functional stress testing with
exercise or pharmacological agents may be indicated as supplement to CTA for prognostic stratification and assessment
for revascularization. (J HK Coll Cardiol 2007;15:67-73)
Cancer induction, contrast reaction, coronary computed tomography angiography, functional stress testing, invasive
coronary angiography
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Introduction
Rapid advances in multislice computed
tomography (MSCT) technology in the past few years
have made MSCT coronary angiography (CTA) an
attractive alternative to conventional invasive coronary
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angiography (ICA). The attractiveness of CTA lies in
its ability to rule out significant coronary artery disease
(CAD), thereby avoiding unnecessary ICA. Advances
in CTA required the development of protocols consistent
with rapid incremental improvements in CT technology.
Parameters such as gantry rotation time, breath holding,
heart rate control, ECG gating, scanning parameters,
multiplanar image reconstruction, image field of view
and contrast injection techniques are taken into
consideration. 1 With proper patient selection and
appropriate protocols in the use of a new generation of
64-slice CT scanners, sensitivity of 83% to 99% and
specificity of 93% to 98% in comparison with ICA have
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been reported. The high negative predictive value of
95% to 100% confirms the value of CTA in ruling out
significant CAD.2 It has been proposed that even though
the effective radiation dose from CTA is higher than
ICA, the risk of mortality from radiogenic and nonradiogenic risks combined in ICA (0.02% and 0.11%
respectively) yields a 0.13% overall risk, which is nearly
twice as high as the radiogenic mortality risk of 0.07%
from CTA.3

Hong Kong dollars), there is a danger that CTA may be
overused as screening tests for asymptomatic patients
with no significant risk factors of CAD, thereby exposing
them to the dangers of (1) contrast reaction, (2) excessive
radiation exposure and (3) false positive test result with,
the risks of invasive coronary angiography that follows.
The worst possible complications are fatal reaction to
iodinated contrast agents and fatal cancer induction such
as leukemia from excessive radiation exposure.

Patient Selection

Adverse Reactions to Iodinated
Contrast Agents

To undergo CTA, patients must be able to lie still,
follow breath-holding instructions (6 to 20 seconds) and
have no irregular rhythm and no contraindication to
iodinated contrast agents. They should be able to tolerate
beta blockers if necessary to lower the heart rate to
around 60 per minute and nitroglycerine to enhance
image quality. Heavy calcification (calcium score 400
or more) or presence of stent in the coronary arteries
may obscure the lumens. Analyses is usually limited to
segments with diameter of over 1.5 mm. A new advance
in technology for 64-slice CTA is to use 2 sets of X-ray
tubes and detectors (dual source) instead of one to
improve temporal resolution and reduce the problems
caused by motion artefacts.4 256-slice CTA with 0.5 mm
collimation and expanded field of view has been
developed, which has the potential to visualize wall
motion, ejection fraction, myocardial perfusion in
addition to the evaluation of coronary arteries with the
same injection of iodine, resulting in less radiation
exposure to the patient.5

Risks of CTA
Heart disease has ranked second to cancer as a
major cause of death in Hong Kong for over four
decades, and sudden death may be the first symptom of
CAD. A screening test which has a high negative value
is therefore very appealing to health-conscious
individuals. As more facilites for MSCT are becoming
available and the cost per CTA examination is coming
down to the affordable level (about four to six thousand

J HK Coll Cardiol, Vol 15

Adverse reactions to iodinated agents range from
mild allergic reaction such as itchiness to life threatening
emergency such as anaphylactic shock. Renal toxicity
is a well known complication. The risk for adverse
reaction is 4% to 12% with ionic contrast agents and
1% to 3% with nonionic contrast agents, and the risk
for severe adverse reaction is 0.16% with ionic contrast
agents and 0.03% with nonionic contrast agents. The
death rate, one to three per 100,000 contrast
administration, is similar for both ionic and nonionic
agents.6 Previous reaction to contrast agents, asthma,
and allergies are factors associated with an increased
risk of developing adverse reaction. Pretreatment of such
patients with corticosteroid and diphenhydramine
decreases the chance of adverse reactions. Prompt
recognition of adverse reactions allow them to be treated
immediately. Using the smallest dose possible with lowosmolar, nonionic agents also reduces the relative risk
of reactions. Contrast-induced nephropathy may be
decreased by ensuring adequate hydration and
discontinuation of nephrotoxic medications such as
metformin before contrast administration.7

Cancer Risk from Radiation
Exposure in CTA
The unit of measurement for effective dose of
radiation is millisievert (mSv). Different tissues and
organs in the body have different sensitivity to radiation
exposure, and the actual dose to different parts of the

October 2007

68

CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY

body during an X-ray procedure also varies. The term
effective dose is used when referring to the dose
averaged over the entire body. The average exposure to
natural background radiation (from external terrestial
radiation, cosmic radiation and radioisotopes within the
body) is about 1 mSv per person per year at sea level.
This does not include the background radiation of about
1.2 to 2.0 mSv per year delivered to the lungs from radon
gas in buildings. The maximal permissible levels that
are recommended by the National Council on Radiation
Protection and Measurements (NCRP) in the United
States for people exposed to radiation (other than
background radiation and from medical applications)
are 1 mSv per year for the general public and 50 mSv
per year for radiation workers employed by nuclearrelated industries.
The risk of cancer after low doses of ionizing
radiation has been studied in survivors of atomic bombs
in Japan, in nuclear workers, and in diagnostic
X-rays.8-10 The lowest dose of X- or gamma radiation
for which good evidence of cancer risk exists is
approximately 10-50 mSv for an acute exposure and
50-100 mSv for a protracted exposure.11 Coles et al
reported the effective radiation doses from various
coronary diagnostic image studies as follows: ICA
(5.6 mSv), CTA (14.7 mSv), calcium score scanning
(2.6 mSv), positron emission tomography (PET) scan
(8.0 mSv), single-photon emission computed
tomography (SPECT) imaging with 201 thallium (18.0
mSv), (10 to 12 mSv with technetium 99 sestamibi).12
Hausleiter et al estimated the effective dose from 16slice CTA is 6.4 mSv and that from a 64-slice CTA is
11.0 mSv.13 Modulation techniques gated to ECG may
reduce the radiation exposure of CTA by about 40-60%.
The US Food and Drug Administration cautioned
that typical values cited for radiation dose should be
considered as estimates that cannot be precisely
associated with any individual patient, examination, or
type of CT system. The actual doses from a procedure
could be two or three times larger or smaller than the
estimates. For comparison, the typical effective dose
for a chest X-ray is 0.02 mSv, skull X-ray (0.07 mSv),
screening mammogram (0.13 mSv), lumbar spine (1.3
mSv), IV urogram (2.5 mSv), upper GI exam (3.0 mSv),
barium enema (7.0 mSv), CT head (2.0 mSv), CT
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abdomen (10.0 mSv). 14 The estimated dose range
received by Japanese survivors of atomic bombs, who
have demonstrated a small but definite risk of fatal
cancer, is 5 to 20 mSv.
Based on experimental studies, it is believed that
the most important type of lesions induced by ionizing
radiation is breaks in double-stranded DNA, resulting
in induction of point mutations, tumour-suppressor gene
inactivation, or chromosomal translocation. The
mutation in cancers and their growth characteristics are
not distinguishable from spontaneously occuring
cancers of the same sites, and have long latent periods.
This explains why there are many uncertainties in the
risk estimation of cancer from low doses of ionizing
radiation, (unlike for example, mesothelioma and
its association with asbestos exposure). Radiation
protection agencies such as the International
Commission on Radiological Protection (ICRP) have
adopted the hypothesis that there is no safe lower limit
or threshold to the cancer-causing (stochastic) effect of
low dose ionizing radiation in their approach to risk
management.15
The US Food and Drug Administration Center
for Devices and Radiological Health estimated that a
CT examination with an effective dose of 10 mSv may
be associated with a 1 in 2000 chance of developing
fatal cancer.14 ICRP estimated that CTA with an effective
dose of 14.7 mSv has a risk of fatal cancer induction
rate of 1 in 1400. Invasive coronary angiography (5.6
mSv) has a fatal cancer risk of 1 in 3600 and calcium
scoring scan (2.6 mSv) has a fatal cancer risk of 1 in
7700. The BEIR VII report in 2006 doubled the cancer
risk of a 10 mSv CT to 1 in 1000.8 The risk in children
is even higher with a reported chance of 1 in 550. BEIR
VII reported that the malignancies most associated with
X-ray exposure are leukemia, thyroid and breast cancer.
The latent period between exposure and the development
of cancer was reported as 2 to 5 years for leukemia and
10 to 20 years for solid tumours. In comparison, the
natural risk of developing fatal cancer in the US
population is about 1 chance in 5. In Hong Kong, the
natural risk of developing fatal cancer for the general
population is about 1 in 3. In other words, the risk of
developing cancer from CT radiation exposure is much
smaller than the natural risk of cancer. Nevertheless,
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this small increase can become a public health concern
if large numbers of the general population undergo
increased numbers of CT screening procedures that have
no certain health benefit. For individuals in whom
interventional radiology procedures are life-saving, the
risks associated with radiation exposure are secondary
in importance. One area in which the risk of radiation
exposure is clearly unjustified is CTA screening of
healthy asymptomatic individuals with low risk factors
for CAD.
Strauss et al (Memorial Sloan-Kettering Cancer
Center, New York) made a calculation on the riskbenefits of CTA and concluded that 'the risk of radiation
has its reward.' They contented that if the entire
18,800,000 people comprising the 50 to 55 year-old
population were screened for CAD using CTA, the
increase in the number of fatal cancers would be
14,900. If this screening were repeated every 5 years
until the population reached the age of 70, the aggregate
risk would be increased by about threefold to 42,900.
Because the average age of patients with their first
myocardial infarction is 65.8 for men and 70.4 for
women and because 94% of these patients would have
over 75% stenosis in at least one vessel, these sequential
CTA procedures could identify patients with significant
stenoses before their initial events. If this procedure
prevented even 10% of the estimated 355,000 sudden
deaths from CAD each year, the trade off would be well
worthwhile.3
On the other hand, if we consider that over half
of the patients who died of sudden death from CAD
had coronary lesions that are less than 50% stenosed,
due to rupture of soft, non-calcified vulnerable
atheromatous plaques resulting in sudden platelet
aggregation and thrombosis of the coronary artery, the
benefit of CTA and subsequent interventions in reducing
the rate of sudden cardiac deaths may be over-estimated.
As yet the place of identifying the vulnerable plaques
with CTA and its clinical applications are uncertain.
For example, Boden et al found in the COURAGE study
(which was presented in ACC 07 in March in New
Orleans) that among patients with stable coronary
disease, treatment with percutaneous coronary
intervention (PCI) was not associated with a difference
in death or myocardial infarction compared with
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intensive medical therapy through 5 years of followup.16 To combat CAD for the health of the community,
priority should be given to prevention through control
of the risk factors of CAD.

When Is It Appropriate to Do a CTA?
To answer this question, the American College
of Cardiology Foundation (ACCF) in conjunction with
the American College of Radiology and related Societies
have recently published their consensus on the
appropriateness of cardiac computed tomography and
cardiac magnetic resonance imaging.17 The section on
CTA for chest pain syndrome is summarized as follows:
1. The use of CTA for evaluation of chest pain
syndrome is considered appropriate if the patient is
(1) symptomatic, (2) has an intermediate pre-test risk
of CAD and 3) has one of the following: (a) has an
uninterpretable ECG and is unable to exercise, (b) has
no ECG changes and serial cardiac enzymes were
negative while under observation for acute coronary
syndrome, or (c) has previously an uninterpretable or
equivocal stress test (exercise, perfusion, or stress echo).
Uninterpretable ECG refers to ST-segment depression
of 0.10 mV or greater in resting ECG, complete LBBB,
WPW syndrome, or paced rhythm.
'Symptomatic' means that the patient has chest
pain syndrome which includes chest pain, chest
tightness, burning, dyspnea, shoulder pain, jaw pain,
and perhaps pain radiating to the back as well.
'Pre-test Probability of CAD' is evaluated as
follows and is based on the characteristics of the chest
pain, as proposed originally by Diamond and Forrester in
1979:18
1) Typical Angina if it is: (a) substernal (b) provoked
by exertion or emotional stress and (c) relieved by
rest and/or nitroglycerin.
2) Atypical Angina if the chest pain or discomfort has
only 2 out of 3 of the characteristics of typical
angina.
3) Nonanginal Chest Pain if chest pain or discomfort
has only one or none of the 3 characteristics of
typical angina.
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An intermediate pre-test probability of CAD also
takes sex and age into consideration and is calculated
as follows:
Pre-test probability of CAD is Intermediate for
(a) men 30-39 with typical angina and (b) men 40
and above with atypical angina or nonanginal chest
pain.
Pre-test probability of CAD is Intermediate for
(a) women 40-49 with typical angina, (b) women 5059 with atypical angina, and (c) women 60 and above
with nonanginal chest pain.
The rationale for this strategy is that a majority
of patients in this group will have negative finding from
CTA, and they will be spare from the risks of ICA.
2. The use of CTA for the evaluation of chest pain
syndrome is considered inappropriate if the patient
is symptomatic and has (a) high pre-test probability of
CAD, or (b) there is ECG ST elevation or positive
cardiac enzymes while under observation for acute
coronary syndrome, or (c) if previous evaluation for
chest pain syndrome showed evidence of moderate or
severe ischemia on stress test (exercise, perfusion, or
stress echo). Pre-test probability of CAD is considered
high (a) for men aged 40 and above with typical angina
and (b) for women aged 60 and above with typical
angina.
Here, the rationale is that these patients have a
high likelihood of significant CAD and will be better
served by going straight for ICA, thereby avoiding extra
expenses and extra radiation from CTA.
3. The use of CTA is also considered inappropriate
for asymptomatic patients with low or moderate risk of
coronary heart disease (CHD) based on the Framingham
Risk Score.19,20 The Framingham risk stratification for
CHD is based on age and 5 other risk factors: high LDL
cholesterol, low HDL cholesterol, hypertension,
diabetes and smoking. There are different sets of criteria
for men and women. The risk is 'high' if the total points
indicate that the 10 year risk of CHD is greater than
20%, 'moderate' if the risk is between 10% and 20%,
and 'low' if the probability is <10%. The risk of CTA is
not justified if the pre-test likelihood of CHD is not
high.
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A rough calculation of risks for CHD (without
referring to the CHD prediction score sheet) is as
follows: For men age 60 and above, 'high' is 2 out of 5
risk factors present; and 'moderate' is 1 out of 5 risk
factors present. For women aged 60 and above, 'high' is
3 out of 5 risk factors present; and moderate is 2 out of
5 risk factors present.
4. The appropriateness of CTA is considered
uncertain if the patient is asymptomatic but has high
CHD risk according to the Framingham score. Opinion
was divided whether the patients should just receive
intensive risk reduction medical therapy, or undergo
stress testing (exercise, perfusion or stress echo) or CTA.

CTA or Stress Testing?
In the course of evaluating a patient with chest
pain and intermediate risk of CAD, current guidelines
from the American College of Cardiology and American
Heart Association suggest that noninvasive testing may
be of use for both diagnostic and prognostic purposes.21-26
Logically one should start with the basic and most
economical test, such as a regular stress exercise ECG
with attention to functional capacity, heart rate response
during and after exercise, and ventricular ectopy, which
are more important predictors of risk than ST segment
depression.27 Many physicians, however, are attracted
by the innovation of CTA. Fear of missing a significant
coronary lesion leading to sudden death is a potent
incentive but no tests are ever fool-proof. CTA provides
direct visualization of coronary stenosis but provides
no adequate information on the hemodynamic
significance of the stenotic lesions. In other words, it
identifies atherosclerosis but not ischemia. No long term
prognostic data are yet available for CTA with the
exception of coronary calcium score. On the other hand,
there are ample data for prognostic stratification with
the various forms of stress testing.
In a study comparing CTA with stress myocardial
perfusion imaging (MPI) using gated SPECT with
technetium 99, with both tests completed within 30 days
of each other, Schuijf et al found that 90% of the patients
with normal CTA also had normal MPI; but in patients
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with obstructive CAD (luminal stenosos of 50% or
more) on CTA, 50% were found to have normal MPI.
The latter finding indicates that CTA and MPI provide
different information on CAD, namely atherosclerosis
versus ischemia. 28 In the accompanying editorial,
Dorbala et al wrote that the enthusiasm for CTA as a
potential noninvasive tool for guiding patient
management decisions is tempered by a growing
awareness that CTA may be limited in defining
physiologic significance of coronary stenosis. Therefore
in patients with obstructive CAD on CTA, MPI would
be necessary to identify appropriate candidates for ICA
and revascularization, since revascularization would not
yield benefit in patients who have no objective evidence
of ischemia, or only small amounts of ischemic
myocardium. The substantial radiation burden from
combined evaluation with CTA (7 to 12 mSv) and MPI
(15 mSv) needs to be considered.29
In another study, patients with acute chest pain
(at low risk of acute coronary syndrome after initial
assessment in an emergency center) were randomized
into two groups: (1) initial CTA, followed by nuclear
stress MPI if indicated and (2) nuclear stress MPI. CTA
was able to establish or exclude CAD as the cause of
chest pain in nearly 75% of cases. Patients with
intermediate lesions of unclear hemodynamic
significance (defined as stenosis = 26% to 70%) or nondiagnostic CTA scans underwent nuclear stress MPI.
Patients with insignificant lesions on CTA or MPI were
sent home. Patients with a stenosis of 70% or more and
those with abnormal MPI underwent ICA, and
ultimately 95% had a correct and definitive diagnosis.
The patients randomized to primary nuclear stress MPI
who had normal tests were immediately discharged
(95% of patients), and those with an abnormal MPI test
results underwent ICA. No major adverse events were
reported in either group of patients who were sent home
during 6 months of follow-up, indicating the safety of
such measures.30
The initial CTA approach was associated with
the necessity for 25% of patients to undergo radiation
exposure twice (15 to 28 mSv), with a further 4 to
6 mSv for the 10% of patients referred for ICA. An
alternative, if initial CTA does not give a definitive
diagnosis, would be to use other stress tests that avoid
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radiation exposure such as exercise ECG, dobutamine
stress echo, or magnetic resonance stress testing. A
benefit of the CTA approach in the assessment of acute
chest pain in the emergency setting is that other
potentially fatal conditions such as acute coronary
occlusion, aortic dissection and pulmonary embolism
may be picked up or excluded (triple rule-out). This
would require a CT scan protocol with a large field of
view allowing global evaluation of thoracic structures,
and the draw back is that it would compromise the
evaluation of the coronaries and might lead to
misinterpretation of coronary lesions.31
It is clear that CTA and stress testing are
complementary diagnostic tools in the investigation of
patients with chest pain and intermediate likelihood of
CHD. One cannot replace the other. The technology of
MSCT is still progressing. 256-slice CTA, hybrid
machines such as PET/CT and SPECT/CT are now
available, and further studies will be necessary to
determine how best to use these new diagnostic
techniques. Their cost-effectiveness also need to be
addressed. Referring physicians should be educated on
the hazards of radiation exposure in CTA and nuclear
scans. Patient disclosure of radiation risks for CTA and
nuclear MPI study should be adopted. The possibility
of alternative methods of clinical evaluation and stress
testing which do not involve the risks of contrast reaction
and radiation exposure should be discussed with the
patients.
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